Early Safety Findings Among Persons Aged ≥60 Years
V-safe and VAERS systems monitor RSV vaccine reactions in U.S. adults ≥60 years. From May 3, 2023–April 14, 2024, 16,220 V-safe participants reported symptoms post-vaccination, with 39.0% possibly related to RSV vaccination. VAERS received 3,200 adverse event reports, 8.8% serious, including 34 deaths. GBS cases were noted post-GSK and Pfizer vaccines.
Reference News
Early Safety Findings Among Persons Aged ≥60 Years
V-safe and VAERS systems monitor RSV vaccine reactions in U.S. adults ≥60 years. From May 3, 2023–April 14, 2024, 16,220 V-safe participants reported symptoms post-vaccination, with 39.0% possibly related to RSV vaccination. VAERS received 3,200 adverse event reports, 8.8% serious, including 34 deaths. GBS cases were noted post-GSK and Pfizer vaccines.